¼¼°èÀÇ ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀå
Neglected Tropical Diseases Diagnosis
»óǰÄÚµå : 1659303
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 89 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,301,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,905,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀåÀº 2030³â±îÁö 103¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 74¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀåÀº 2024-2030³â¿¡ CAGR 5.6%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 103¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ±âÁ¸¹ýÀº CAGR 4.9%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 54¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºÐÀÚ/ÃֽŹý ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 6.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 19¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀåÀº 2024³â¿¡ 19¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 22¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 8.2%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.6%¿Í 4.4%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¹«½Ã´çÇÏ´Â ¿­´ë¼º Áúº´ Áø´ÜÀÌ ¼¼°è º¸°Ç¿¡ Áß¿äÇÑ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

¼Ò¿Ü¿­´ëÁúȯ(Neglected Tropical Diseases, NTDs)Àº ÁÖ·Î Àú¼Òµæ Áö¿ª ÁֹεéÀÌ ÁÖ·Î ¾Î°í ÀÖ´Â ´Ù¾çÇÑ °¨¿°¼º ÁúȯÀ» Æ÷ÇÔÇϸç, µ­±â¿­, ¸®½´¸¸º´, »þ°¡½ºº´, ÁÖÇ÷ÈíÃæÁõ µî NTDsÀÇ Á¤È®ÇÑ Áø´ÜÀº À̵é ÁúȯÀ» Á¦¾ÐÇϰí ÅðÄ¡ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ±ÙÀýÇϱâ À§ÇØ ÇʼöÀûÀÔ´Ï´Ù. Á¶±â¿¡ Á¤È®ÇÑ Áø´ÜÀº ÇÕº´Áõ ¿¹¹æ, Àü¿° °¨¼Ò, È¿°úÀûÀÎ Ä¡·á¿¡ µµ¿òÀÌ µË´Ï´Ù. ÀüÅëÀûÀ¸·Î NTDsÀÇ Áø´ÜÀº Á¦ÇÑµÈ ÀÚ¿ø, ÀÎÇÁ¶ó ºÎÁ·, Àü¹® ÀåºñÀÇ Çʿ伺 µîÀ¸·Î ÀÎÇØ ¾î·Á¿ü½À´Ï´Ù. ±×·¯³ª ½Å¼ÓÁø´Ü°Ë»ç(RDT), ºÐÀںм®, ÇöÀåÁø´Ü±â±â µî Áø´Ü±â¼úÀÇ Çõ½ÅÀ¸·Î NTDsÀÇ Áø´ÜÀÌ º¸´Ù ½Å¼ÓÇϰí Á¤È®ÇØÁ³À¸¸ç, ¿ø°ÝÁö¿¡¼­µµ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÊ¿¡ µû¶ó NTDsÀÇ Áø´Ü¿¡ º¯È­°¡ ÀϾ°í ÀÖ½À´Ï´Ù.

NTD Áø´Ü ½ÃÀåÀÇ ÁÖ¿ä ºÎ¹®Àº?

Áø´Ü ±â¼ú¿¡´Â Ç÷ûÇÐÀû °Ë»ç, ºÐÀÚ°Ë»ç, ¿µ»ó Áø´Ü µîÀÌ ÀÖ½À´Ï´Ù. Ç×ü³ª Ç׿øÀ» °ËÃâÇÏ´Â Ç÷ûÇÐÀû °Ë»ç´Â µ­±â¿­À̳ª ¸®½´¸¸º´°ú °°Àº Áúº´¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¹Ý¸é ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ(PCR)°ú °°Àº ºÐÀÚ°Ë»ç´Â »þ°¡½ºº´À̳ª ÁÖÇ÷ÈíÃæÁõ°ú °°Àº Áúº´À» Á¤È®ÇÏ°Ô °ËÃâÇϱâ À§ÇØ ¼±È£µÇ°í ÀÖ½À´Ï´Ù. Áúº´ À¯Çüº°·Î´Â ±â»ýÃæ¼º, ¹ÙÀÌ·¯½º¼º, ¼¼±Õ¼º NTDs¸¦ Æ÷°ýÇϰí ÀÖÀ¸¸ç, ±â»ýÃæ¼º NTDs´Â ¹ßº´ Áö¿ª¿¡¼­ÀÇ À¯ÇàÀ¸·Î ÀÎÇØ °¡Àå Å« ºÎ¹®À» Â÷ÁöÇϰí ÀÖÀ¸¸ç, NTD Áø´ÜÀÇ ÁÖ¿ä ÃÖÁ¾»ç¿ëÀÚ´Â º´¿ø, Áø·á¼Ò, °øÁß º¸°Ç ¿¬±¸¼Ò, ¿¬±¸ ±â°ü µîÀ» Æ÷ÇÔÇÕ´Ï´Ù. Àº Áúº´ °¨½Ã ¹× Ä¡·á Àü·« °³¼±¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀº NTD Áø´ÜÀ» ¾î¶»°Ô °­È­Çϴ°¡?

±â¼ú Çõ½ÅÀº NTD Áø´Ü °³¼±ÀÇ ÃÖÀü¼±¿¡ ÀÖ½À´Ï´Ù. ½Å¼ÓÁø´Ü°Ë»ç(RDT)´Â ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ¸·Î µîÀåÇÏ¿© ¸î ºÐ ¾È¿¡ °á°ú¸¦ ¾òÀ» ¼ö ÀÖÀ¸¹Ç·Î ÀÇ·á ÀÎÇÁ¶ó°¡ Á¦ÇÑµÈ ¿ø°ÝÁö¿¡¼­µµ ½Å¼ÓÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ½Ç½Ã°£ PCRÀ̳ª LAMP(loop-mediated isothermal amplification)¿Í °°Àº ºÐÀÚÁø´Ü¹ýÀº ³ôÀº ¹Î°¨µµ¿Í ƯÀ̼ºÀ» Á¦°øÇϹǷΠÁ¤È®ÇÑ Áúº´ ¹ß°ß¿¡ ÇʼöÀûÀÔ´Ï´Ù. ¸ð¹ÙÀÏ ±â¹Ý Áø´Ü ŰƮ ¹× AI ±â¹Ý Áø´Ü ¾Ë°í¸®Áò°ú °°Àº µðÁöÅÐ °Ç°­ Åøµµ NTD °¨¿° Áö¿ª¿¡¼­ Áúº´ °¨Áö, µ¥ÀÌÅÍ ¼öÁý ¹× º¸°í¸¦ °­È­Çϱâ À§ÇØ µµÀԵǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº Áø´ÜÀ» °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó NTD ÅðÄ¡¸¦ À§ÇÑ Àü ¼¼°è ³ë·Â¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¹«½Ã´çÇÏ´Â ¿­´ëº´ Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

¼Ò¿ÜµÈ ¿­´ë¼º Áúȯ Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº ÁßÀú¼Òµæ ±¹°¡¿¡¼­ NTDsÀÇ ºÎ´ã Áõ°¡, Á¤È®Çϰí Àú·ÅÇÑ Áø´Ü Åø¿¡ ´ëÇÑ ±ä±ÞÇÑ ¼ö¿ä µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇϰí ÀÖ½À´Ï´Ù. ´õ ³ªÀº °¨½Ã¿Í Áø´ÜÀ» ÅëÇØ NTDs¸¦ ÅëÁ¦ÇÏ°í ±ÙÀýÇϱâ À§ÇÑ Á¤ºÎ ¹× ºñÁ¤ºÎ±â±¸ÀÇ ³ë·ÂÀº Çõ½ÅÀûÀÎ Áø´Ü Åø¿¡ ´ëÇÑ ¼ö¿ä¸¦ Å©°Ô Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ÈÞ´ë¿ë Áø´Ü ±â±â ¹× ÇöÀå °Ë»ç µîÀÇ ±â¼ú ¹ßÀüÀ¸·Î ÀÚ¿øÀÌ ºÎÁ·ÇÑ È¯°æ¿¡¼­µµ NTD Áø´ÜÀÌ º¸´Ù ½±°Ô ÀÌ·ç¾îÁú ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ¼¼°èº¸°Ç±â±¸(WHO)¿Í ºô & ¸á¸°´Ù °ÔÀÌÃ÷ Àç´Ü(Bill &&Melinda Gates Foundation)°ú °°Àº ¼¼°è º¸°Ç ±¸»óÀÇ ±¹Á¦ÀûÀÎ ÀÚ±Ý Áö¿øÀº NTD Áø´ÜÀÇ ¿¬±¸°³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ 1Â÷ ÀÇ·á ½Ã½ºÅÛ¿¡ ´ëÇÑ Áø´Ü¾à¹° ÅëÇÕ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

¹æ½Ä(±âÁ¸, ºÐÀÚ/ÃÖ½ÅÇü);& ¼­ºñ½º À¯Çü(Áß¾ÓÁýÁßÇü, Point of Care);& ÃÖÁ¾»ç¿ëó(ÀÓ»ó°Ë»ç½Ç, º´¿ø/Ŭ¸®´Ð, ÀçÅÃÀÇ·á)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 33»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Neglected Tropical Diseases Diagnosis Market to Reach US$10.3 Billion by 2030

The global market for Neglected Tropical Diseases Diagnosis estimated at US$7.4 Billion in the year 2024, is expected to reach US$10.3 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Conventional Method, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$5.4 Billion by the end of the analysis period. Growth in the Molecular / Modern Method segment is estimated at 6.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.9 Billion While China is Forecast to Grow at 8.2% CAGR

The Neglected Tropical Diseases Diagnosis market in the U.S. is estimated at US$1.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 4.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Neglected Tropical Diseases Diagnosis Market - Key Trends and Drivers Summarized

Why Is Neglected Tropical Diseases Diagnosis Crucial for Global Health?

Neglected Tropical Diseases (NTDs) encompass a range of infectious diseases that predominantly affect populations in low-income regions. Accurate diagnosis of NTDs is critical for controlling and eradicating these diseases, which include conditions like dengue, leishmaniasis, Chagas disease, and schistosomiasis. Early and precise diagnosis helps prevent complications, reduces transmission, and aids in effective treatment. Traditionally, diagnosing NTDs has been challenging due to limited resources, lack of infrastructure, and the need for specialized equipment. However, innovations in diagnostic technologies, such as rapid diagnostic tests (RDTs), molecular assays, and point-of-care devices, are transforming NTD diagnosis by making it faster, more accurate, and accessible in remote areas.

What Are the Key Segments in the NTD Diagnosis Market?

Diagnostic techniques include serological tests, molecular tests, and imaging-based diagnostics. Serological tests, which detect antibodies or antigens, are widely used for diseases like dengue and leishmaniasis, while molecular tests, such as polymerase chain reaction (PCR), are preferred for their accuracy in detecting diseases like Chagas and schistosomiasis. In terms of disease type, the market covers parasitic, viral, and bacterial NTDs, with parasitic NTDs being the largest segment due to their prevalence in affected regions. Major end-users of NTD diagnostics include hospitals, clinics, public health laboratories, and research institutions that are focused on improving disease surveillance and treatment strategies.

How Are Technological Innovations Enhancing NTD Diagnosis?

Technological advancements are at the forefront of improving NTD diagnosis. Rapid diagnostic tests (RDTs) have emerged as a cost-effective solution, offering results within minutes and facilitating quick decision-making in remote areas with limited healthcare infrastructure. Molecular diagnostics, such as real-time PCR and loop-mediated isothermal amplification (LAMP), offer high sensitivity and specificity, making them essential for accurate disease detection. Digital health tools, including mobile-based diagnostic kits and AI-powered diagnostic algorithms, are also being deployed to enhance disease detection, data collection, and reporting in NTD-affected regions. These technologies not only improve diagnosis but also contribute to global efforts toward NTD elimination.

What Factors Are Driving the Growth in the Neglected Tropical Diseases Diagnosis Market?

The growth in the Neglected Tropical Diseases Diagnosis market is driven by several factors, including the increasing burden of NTDs in low- and middle-income countries and the urgent need for accurate, affordable diagnostics. Government and non-governmental organizations' efforts to control and eliminate NTDs through better surveillance and diagnosis have significantly boosted the demand for innovative diagnostic tools. Technological advancements, such as portable diagnostic devices and point-of-care testing, have made NTD diagnosis more accessible, even in resource-constrained settings. Additionally, international funding from global health initiatives, such as the World Health Organization and the Bill & Melinda Gates Foundation, is promoting research and development in NTD diagnostics. The increasing focus on integrating diagnostics into primary healthcare systems is also driving market growth.

SCOPE OF STUDY:

The report analyzes the Neglected Tropical Diseases Diagnosis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Method (Conventional, Molecular / Modern); Service Type (Centralized, Point of Care); End-Use (Clinical Labs, Hospitals & Clinics, Home Healthcare)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 33 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â